Compare American Express Co (AXP) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Express Co vs Pfizer Inc — how do they compare? American Express Co trades at $340.62 (market cap $230.15B), while Pfizer Inc trades at $26.22 (market cap $151.73B). The key difference: American Express Co is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.46%). Which is the better fit depends on your goals.
| AXP | PFE | |
|---|---|---|
Market Cap | $230.15B | $151.73B |
Sector | Financials | Health |
52-Week High | $384.82 | $28.56 |
52-Week Low | $292.27 | $23.60 |
Dividend Yield | 1.11% | 6.46% |
Volume | — | 29,869,932 |
Enterprise Value | — | $203.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Express (AXP) trades at $338.86, down 0.6% with bearish technical signals despite strong fundamentals. The company reported solid Q2 2026 earnings beat ($4.53 vs $4.41 expected) and maintains robust profitability with 15.07% net margin and 33.97% ROE. Recent news highlights Amex Ventures' AI investments and premium card member experiences, while Berkshire Hathaway's 20% ownership underscores long-term confidence in the business model.
AXP presents a mixed outlook with strong fundamental performance offset by technical weakness. The stock offers 9% upside to consensus price target of $369.42, supported by revenue growth and premium positioning, but faces headwinds from bearish technical indicators and competitive pressure in digital payments. Risk-reward appears balanced near current levels.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Express Co
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
